Latisse, owned by Allergan, is a topical medication used for enhancing the growth of hair, including eyelashes. The active ingredient in Latisse is bimatoprost. The drug was first authorised for market use on December 24, 2008.
The last patent protecting Latisse is set to expire on May 25, 2024, paving the way for the potential introduction of generics. The generic version of Latisse could be released after this date, depending on Para IV filings and litigation outcomes.
Latisse has various uses including increasing the growth of hair and eyelashes, promoting increased eyelash growth in terms of length, thickness, darkness and number by administering bimatoprost to the eyelid margin. It is also used for the treatment of hypotrichosis of the eyelashes by increasing their growth in terms of length, thickness and darkness.
Latisse holds 8 patents with 7 already expired. The last active patent, US8101161, titled 'Method of enhancing hair growth', is expiring on May 25, 2024. Upon its expiry, the way for Latisse generics will be clear. Below is the detail of the patent: